LAR is a widely expressed receptor-like protein tyrosine phosphatase that is implicated in regulation of intracellular signaling triggered by both cell adhesion and peptide growth factors. Genetic studies revealed that LAR regulates neuron axon path ®nding in Drosophila and mammary gland epithelial cell dierentiation in mice. The molecular mechanism underlying the tissue speci®c function of LAR has not been clearly understood. We investigated the role and mechanism of LAR in peptide growth factors EGF and FGF signaling in human tissue culture cells in which the expression of LAR is under the control of an inducible promoter. We found that although both EGF and FGF induce activation of mitogen-activated protein kinase (MAPK), LAR only inhibits FGF-induced MAPK activation. LAR does not interact directly with the peptide growth factor receptors, since the ligand-induced autophosphorylation of growth factor receptors was not aected by induction of LAR. The speci®c eect of LAR on FGF-induced MAPK activation appeared to be mediated by speci®c inhibition of the phosphorylation of two signal transducers that act downstream of the FGF receptor, FRS2 and a 180 kDa protein, and by prevention of their interaction with the adaptor protein GRB2. In contrast, LAR selectively inhibited the epidermal growth factor (EGF)-induced phosphorylation of p130 CAS and the formation of the complex between p130 CAS and GRB2 but this eect did not in¯uence the activation of MAPK by EGF. These data suggest that LAR and similar receptor-like protein tyrosine phosphatases may contribute to the regulation of transmembrane signaling by selectively inhibiting the tyrosine phosphorylation of speci®c signal transducers that act downstream of the plasma membrane-associated tyrosine kinases. The consequent inhibition of the formation of signaling complexes by these proteins may contribute to the speci®city of the signals generated by speci®c peptide growth factors as well as extracellular matrix proteins.
Introduction
Peptide growth factors elicit distinct biological responses in cells through the activation of speci®c signaling molecules (Chao, 1992; Fantl et al., 1993; van der Geer et al., 1994; Marshall, 1995; Cohen et al., 1995; Lewis et al., 1998) . The binding of such growth factors to their receptors induces tyrosine phosphorylation of the receptors themselves as well as of their immediate downstream signal transducers. The phosphorylated tyrosine residues of the receptors and the signal transducers serve as scaolds to recruit speci®c cytoplasmic enzymes to the plasma membrane, resulting in the formation of speci®c signaling complexes. These initial tyrosine phosphorylation reactions are important in determining the speci®city of the signaling complexes and the subsequent activation of various signal transduction pathways. Thus, dierent growth factors induce the tyrosine phosphorylation of distinct sets of proteins and the formation of distinct signaling complexes. For example, ®broblast growth factor (FGF) induces the phosphorylation of FRS2, whereas epidermal growth factor (EGF) induces the phosphorylation of SHC (Kouhara et al., 1997; Xu et al., 1998; Carpenter and Cohen, 1990; Boonstra et al., 1995; Wells, 1999) . These dierences de®ne the divergent biological responses induced by dierent growth factors. On the other hand, a single growth factor can also activate dierent signaling pathways and biological responses in dierent cell types, or in the same cell type but under dierent conditions. The precise regulatory mechanisms that underlie the initial tyrosine phosphorylation reactions and the formation of signaling complexes, especially the roles of tyrosine phosphatases in such mechanisms, are not well characterized.
One of the key signaling complexes recruited to the plasma membrane by tyrosine-phosphorylated proteins in response to peptide growth factor stimulation comprises GRB2 and SOS1. The recruitment of the GRB2-SOS1 complex brings it into close contact with RAS, which it activates by catalyzing the conversion of GDP-bound RAS to the GTP-bound form. Activated RAS, in turn, induces a cascade of phosphorylation events that result in the activation of mitogen-activated protein kinase (MAPK) (Ahn, 1993; Seger and Krebs, 1995; Cobb, 1999) . Although this signaling pathway is triggered by all peptide growth factors, the extent and duration of MAPK activation vary. Such subtle dierences are important in determining the biological responses induced by the dierent growth factors (Marshall, 1995) . The molecular mechanisms that underlie these dierences are also not fully understood.
Receptor-like protein tyrosine phosphatases (RPTPs) constitute a family of transmembrane proteins that possess intrinsic protein tyrosine phosphatase activity. These proteins are widely, but dierentially, expressed in a variety of tissues, and their expression is developmentally regulated. Genetic studies in Drosophila, Caenorhabditis elegans, and mouse have shown that RPTPs are important for various cellular functions, including guidance of axon growth (Krueger et al., 1996 , Desai et al., 1996 , cell migration (Zinn, 1998) , cell dierentiation (Schaapveld et al., 1997) , and cell proliferation (Elchebly et al., 1999 , Wallace et al., 1999 . The extracellular domains of many RPTPs are large and contain structural motifs that resemble those of cell adhesion molecules, suggesting that they may mediate cell-cell or cellmatrix interactions (O'Grady et al., 1998; Muller et al., 1999) . The structure, subcellular localization, and biochemical properties of RPTPs suggest that these proteins function to counterbalance receptor tyrosine kinases in the regulation of tyrosine phosphorylationdependent transmembrane signal transduction. Thus, the RPTPs LAR and PTPs are implicated in regulation of signaling in response to insulin, EGF, and other peptide growth factors (Kulas et al., 1995 (Kulas et al., , 1996 Li et al., 1996; Ahmad and Goldstein, 1997; Suarez Pestana et al., 1999) .
LAR is a prototypic RPTP. Its large extracellular domain contains three immunoglobulin (Ig)-like loops followed by eight ®bronectin type III repeats. The intracellular portion of LAR contains two tandem phosphatase domains, of which only the membrane-proximal (D1) domain exhibits phosphatase activity in vitro. LAR is thought to participate in tyrosine phosphorylation-dependent signal transduction and in the regulation of cell growth. Thus, expression of LAR correlates with cell proliferation (Katsura et al., 1995) . Furthermore, overexpression of LAR in cultured cells reduces both the extent of phosphorylation and the stability of p130 CAS , an important signaling protein, as well as induces apoptosis (Weng et al., 1998 (Weng et al., , 1999 . In contrast, suppression of LAR expression with the use of antisense oligonucleotides potentiated signal transduction in response to insulin or EGF (Kulas et al., 1995 (Kulas et al., , 1996 . LAR has also been shown to inhibit insulin signal transduction by directly interacting with the insulin receptor (Ahmad and Goldstein, 1997) . Genetic studies revealed that LAR regulates neuron axon path ®nding (Krueger et al., 1996) as well as mammary gland epithelial cell dierentiation (Schaapveld et al., 1997) . Together, these observations suggest that LAR regulates various tyrosine kinase-activated signaling pathways, although the precise roles and mechanisms of action of LAR in each pathway remain to be de®ned.
To investigate the mechanisms of action of LAR in the regulation of transmembrane signal transduction, we have now examined its roles in EGF and FGF signaling. We demonstrate that LAR does not aect the autophosphorylation of the growth factor receptors directly. Instead, it inhibits the tyrosine phosphorylation of speci®c signal transducers that act downstream of the receptors, and it has distinct eects on signaling complex formation induced by the dierent growth factors. Thus, LAR may play a role in determining the speci®city of peptide growth factor signaling.
Results

Effect of LAR on growth factor-induced activation of MAPK
To investigate the role of LAR in peptide growth factor signaling, we studied human osteosarcoma U2OS cells stably transfected with a tetracycline-suppressible expression vector containing rat LAR cDNA (Weng et al., 1998) . LAR protein was induced 6 ± 9 h after removing tetracycline and the level of LAR reached maximum around 24 h after induction (Figure 1) .
We initially examined the eects of LAR induction on MAPK activation in these U2OS/LAR cells of six peptide growth factors: EGF, platelet-derived growth factor (PDGF), FGF1 (acidic FGF), FGF2 (basic FGF), FGF7 (keratinocyte growth factor), and insulinlike growth factor-1(IGF-1). The U2OS/LAR cells did not respond to FGF7 and IGF-1 and responded weakly to PDGF, in terms of MAPK activation (data not shown), presumably because they do not express or express low level of the corresponding receptors. The responses of the cells to FGF1 and FGF2 appeared similar. We therefore focused our attention in the present study on the function of LAR in FGF2 and EGF signal transduction.
The eect of LAR on activation of MAPK by EGF or FGF2 was investigated by immunoblot analysis with antibodies that speci®cally recognize the activated (phosphorylated) form of the enzyme. The basal level of MAPK tyrosine phosphorylation was slightly increased in the LAR-overexpressing cells (Figures 2a  and 3 ) for unknown reason. Whereas LAR had no obvious eect on EGF-induced activation of MAPK, it markedly inhibited that induced by FGF2 (Figure 2a ). To determine whether the tyrosine phosphatase activity of LAR was required for this inhibition of MAPK activation, we examined the eect of a LAR mutant (LAR-DP) with a truncated phosphatase domain (Weng et al., 1999) . The mutant LAR was similarly expressed in U2OS cells under the control of the tetracycline-suppressible promoter. Expression of the mutant LAR had no eect on MAPK activation induced by either EGF or FGF2 (Figure 2b) , suggesting that the tyrosine phosphatase activity of Figure 1 Induction of LAR expression. LAR transfectant U2OS/LAR cells were maintained in the presence of tetracycline. To induce LAR expression, the U2OS/LAR cells were washed, trypsinized, and then seeded into new tetracycline-free media and cultured for the indicated time periods. Cell lysates of equal number of cells were resolved on SDS ± PAGE and followed by immunoblot analysis with antibody (aLAR-294) to LAR. Three protein bands of LAR, the 190 kDa LAR precursor, the 145 kDa extracellular domain of LAR, and the 85 kDa phosphatase domain of LAR, were detected by the antibody LAR is required for its inhibitory eect on FGF2-induced activation of MAPK.
We then investigated the eects of LAR on the dose dependence and time course of FGF2-induced activation of MAPK. In control U2OS/LAR cells not expressing LAR, an FGF2 concentration of 0.01 ng/ ml was sucient to activate MAPK; however, in LARexpressing cells, a concentration of FGF2 at least 10 times greater (0.1 ng/ml) was required to activate MAPK to a similar extent (Figure 3a ). Densitometric analysis revealed that the maximal extent of MAPK activation (apparent at an FGF2 concentration of 0.5 ng/ml) in the absence of LAR was 2.3 times that apparent in cells expressing LAR. Furthermore, the expression of LAR also shortened the duration of MAPK activation induced by FGF-2 ( Figure 3b ). Similar results were obtained when FGF2-induced activation of MAPK was assessed in the presence of heparin (10 mg/ml) (data not shown), which is normally required for FGF activity; the lack of eect of exogenous heparin was presumably due to the presence of sucient endogenous heparin in the culture medium. The dose-response relation ( Figure 3c ) and time course ( Figure 3d ) for EGF-induced activation of MAPK were not aected by LAR overexpression.
Effect of LAR on receptor autophosphorylation
To investigate the mechanism responsible for the distinct eects of LAR on MAPK activation by FGF and EGF, we ®rst examined the eect of LAR overexpression on ligand-induced receptor autophosphorylation. The U2OS/LAR cells were cultured for 24 h in the absence of tetracycline to induce the expression of LAR and were then stimulated with EGF. The EGFR was immunoprecipitated from cell lysates with speci®c antibodies, and receptor autophosphorylation was assessed by immunoblot analysis with a monoclonal antibody to phosphotyrosine. LAR expression had no eect on EGFR autophosphorylation ( Figure 4a ). Similar analysis revealed that LAR did not aect ligand-induced autophosphorylation of the platelet-derived growth factor receptor (data not shown).
To examine the eect of LAR induction on autophosphorylation of FGF receptors, we initially attempted to immunoprecipitate the receptors with various anti-FGF receptor antibodies. However, none of these antibodies immunoprecipitated a sucient number of FGF receptors from the U2OS/LAR cells for immunoblot analysis. We therefore partially puri®ed FGF receptors with WGA (Imamura et al., 1988) and identi®ed them by immunoblot analysis with speci®c antibodies. Two proteins of 130 and 110 kDa, corresponding to the predicted sizes of FGF receptors, were recognized by antibodies to FGFR1 (Figure 4b ). The extent of tyrosine phosphorylation of both of these proteins was increased after stimulation of cells with FGF2. However, the FGF2-induced tyrosine phosphorylation of neither protein was aected by LAR Figure 2 Eect of LAR on MAPK activation by FGF2 or EGF. U2OS/LAR (a) and U2OS/LAR-DP (b) cells that had been cultured for 24 h in the absence of tetracycline to induce LAR or LAR-DP expression, as well as control cells cultured in the presence of tetracycline, were incubated for 10 min in the absence (None) or presence of EGF (25 ng/ml) or FGF2 (5 ng/ml) as indicated. Cell lysates were then prepared and subjected to immunoblot analysis with antibodies speci®c for phosphorylated MAPK (MAPK-P); the blot was subsequently reprobed with antibodies to LAR (aN-130) to verify LAR expression, and to tubulin to verify equal protein application to each lane Figure 3 Eects of LAR on the dose dependence and time course of MAPK activation by FGF2 or EGF. U2OS/LAR cells that had been cultured for 24 h in the absence of tetracycline to induce the expression of LAR, as well as control cells cultured in the presence of tetracycline, were incubated for 10 min in the presence of the indicated concentrations of FGF2 (a) or EGF (c). Alternatively, the cells were incubated for the indicated times in the presence of FGF2 (1 ng/ml) (b) or EGF (25 ng/ml) (d). Cell lysates were then prepared and subjected to sequential immunoblot analysis with antibodies speci®c for the phosphorylated form of MAPK (MAPK-P) or for tubulin induction (Figure 4b) . Together, these results indicated that the EGF and FGF receptor tyrosine kinases are not direct targets of LAR action.
Effects of LAR on growth factor-induced recruitment of GRB2
We next examined the eect of LAR induction on signaling events downstream of the receptors but upstream of MAPK. Given that both FGF and EGF activate MAPK through recruitment of the SRC homology 2 (SH2) domain-containing adaptor protein GRB2 by various tyrosine-phosphorylated proteins (Lowenstein et al., 1992; Schlessinger, 1994; Kouhara et al., 1997) , we analysed the eect of LAR induction on the growth factor-induced association of GRB2 with tyrosine-phosphorylated proteins.
LAR-expressing and control U2OS/LAR cells were stimulated with FGF2 or EGF, lysed, and subjected to immunoprecipitation with antibodies to GRB2. The tyrosine-phosphorylated proteins present in the GRB2 immunoprecipitates were then examined by immunoblot analysis with antibodies to phosphotyrosine. FGF2 induced the association of GRB2 with two major tyrosine-phosphorylated proteins of 180 and 90 kDa, and the extent of GRB2 association with both of these proteins was markedly inhibited by LAR overexpression (Figure 5a ). In contrast, EGF induced the association of GRB2 with a distinct set of four tyrosine-phosphorylated proteins of 170, 130, 52 and 46 kDa, and only the interaction of GRB2 with the 130-kDa protein was inhibited by LAR (Figure 5a ).
FGF-induced activation of MAPK is thought to be mediated by tyrosine phosphorylation of FRS2, a 90-kDa signal transducer downstream of the FGF receptor, and by the subsequent association of this protein with GRB2 (Kouhara et al., 1997) . To determine whether the 90-kDa protein whose association with GRB2 was inhibited by LAR was FRS2, we stimulated LAR-expressing or control U2OS/LAR cells with FGF2 and then precipitated FRS2 from cell lysates with the use of agarose conjugated with p13 SUC1 , Figure 4 Eect of LAR on autophosphorylation of growth factor receptors. LAR expression was induced (or not) by culture of U2OS/LAR cells in the absence (or presence) of tetracycline for 24 h. The cells were then incubated for 10 min in the absence (7) or presence (+) of EGF (10 ng/ml) (a) or FGF2 (1 ng/ml) (b), after which cell lysates were prepared. The EGFR (a) and FGF receptors (b) were subjected to immunoprecipitation (IP) with antibodies to the EGFR (aEGFR) or to precipitation (P) with WGA, respectively, and then to immunoblot analysis with antibodies to phosphotyrosine (aP-Tyr); the same blots were subsequently probed with antibodies either to the EGFR or to FGFR1, respectively Figure 5 Eects of LAR overexpression on the FGF2-or EGF-induced interaction of GRB2 with tyrosine-phosphorylated proteins. (a) U2OS/LAR cells that had been induced to express LAR by culture for 24 h in the absence of tetracycline, as well as control cells cultured in the presence of tetracycline, were incubated for 10 min in the absence or presence of FGF2 (1 ng/ml) or EGF (10 ng/ml) as indicated. Cell lysates were then subjected to immunoprecipitation (IP) with monoclonal antibodies to GRB2, and the resulting precipitates were subjected to sequential immunoblot analysis with monoclonal antibodies to phosphotyrosine (aPTyr) and monoclonal antibodies to GRB2. The sizes (in kilodaltons) of the proteins associated with GRB2 are indicated. (Rabin et al., 1993; Xu et al., 1998 ). The FRS2 precipitates were then subjected to immunoblot analysis with antibodies to phosphotyrosine. Induction of LAR indeed reduced the extent of tyrosine phosphorylation of FRS2 ( Figure 5B ). The identity of the 180-kDa protein whose interaction with GRB2 was also inhibited by LAR remains unknown.
Several tyrosine-phosphorylated proteins have previously been shown to interact with GRB2 in response to EGF stimulation (Boonstra et al., 1995) . These proteins include the EGF receptor itself as well as the p52 and p46 forms of SHC (Pelicci et al., 1992) , which likely correspond to the 170-, 52-, and 46-kDa proteins that interacted with GRB2 in U2OS/LAR cells stimulated with EGF (Figure 5a ). With regard to the identity of the 130-kDa protein whose association with GRB2 was inhibited by LAR, we have previously shown that LAR overexpression reduces the extent of tyrosine phosphorylation as well as the abundance of p130 CAS (Weng et al., 1999) . We therefore examined GRB2 immunoprecipitates from EGF-treated cells for the presence of p130
CAS by immunoblot analysis with speci®c antibodies. The p130 CAS protein was indeed associated with GRB2, and this interaction was inhibited in cells overexpressing LAR (Figure 5c ).
These observations indicated that the distinct eects of LAR on FGF and EGF-induced MAPK activation is caused by its selective interaction with dierent signal transducers downstream of the receptors. Whereas LAR inhibited the interaction of GRB2 with both FRS2 and the 180-kDa protein in FGFstimulated cells, it blocked only the association of GRB2 with p130 CAS in EGF-treated cells.
Association of LAR with phosphorylated FRS2
To investigate the mechanism by which LAR inhibits the interaction of GRB2 with FRS2 and the 180-kDa protein, we examined the possibility that LAR directly interact with FRS2 or/and the 180-kDa protein by coimmunoprecipitation. We immunoprecipitated LAR from the LAR-expressing or control cells with or without FGF2 stimulation and examined the presence of FRS2 and the 180-kDa protein in the LAR immunoprecipitates. There was neither FRS2 nor the 180-kDa protein co-immunoprecipitated with LAR ( Figure 6a and data not shown). We then treated the cells with tyrosine phosphatase inhibitor pervanadate, after which LAR immunoprecipitates were prepared from cell lysates and subjected to immunoblot analysis with antibodies to phosphotyrosine. In the LAR immunoprecipitates prepared from cells stimulated in the presence of pervanadate, three tyrosine-phosphorylated proteins of 180, 130 and 90 kDa were detected (Figure 6a) . Furthermore, the amount of all three proteins co-immunoprecipitated with LAR were increased in the LAR-induced cells, con®rming that the three proteins are physically associated with LAR. The same proteins co-immunoprecipitated with LAR from the uninduced cells are likely due to the low level of endogenous LAR present in the U2OS cells. The mobilities of the three proteins associated with LAR were similar to those of the 180-kDa protein, 130-kDa protein (p130 CAS ), and 90-kDa protein (FRS2) whose interaction with GRB2 was inhibited by LAR.
To further con®rm that LAR indeed directly and physically interact with FRS2 and that the 90-kDa protein detected in the LAR immunoprecipitates was indeed FRS2, we stimulated cells with FGF2 in the absence or presence of pervanadate and then precipitated FRS2 from cell lysates with p13 SUC1 . The resulting precipitates were then subjected to immunoblot analysis with antibodies to LAR. LAR was found to be present in the FRS2 precipitates prepared from cells stimulated in the presence of pervanadate ( Figure  6b ). These results indicate that LAR and FRS2 physically interact in vivo and that the interaction is tyrosine phosphorylation-dependent, suggesting that FRS2 is an in vivo substrate of LAR. LAR directly regulates the extent of tyrosine phosphorylation of FRS2. It is interesting to note that the physical binding of LAR with FRS2 and the other two proteins can only be detected in the presence of the tyrosine Figure 6 Physical interaction between LAR and FRS2. U2OS/LAR cells that had been induced to express LAR by culture for 24 h in the absence of tetracycline, as well as control cells cultured in the presence of tetracycline, were incubated for 10 min in the absence or presence of 200 mM pervanadate and then for 10 min in the absence or presence of FGF2 (1 ng/ml). Cell lysates were then subjected to immunoprecipitation (IP) with antibodies to LAR (a) or to precipitation (P) with GST-p13 SUCI -conjugated agarose beads (b). The resulting precipitates were subjected to immunoblot analysis with antibodies to phosphotyrosine (4G10), or with antibodies to LAR (aN-130) as indicated (Denu et al., 1996) . FRS2 may be quickly released from LAR after dephosphorylation. This transient interaction therefore can not be detected by co-immunoprecipitation. Vanadate can form covalent bond with the active site residue cysteine of PTPs (Denu et al., 1996) . It is possible that the inactivation of the catalytic activity of LAR by vanadate prevents dephosphorylation of FRS2 but does not interfere with the binding of FRS2 to LAR. Since the dephosphorylation of FRS2 is blocked by vanadate, the subsequent release of FRS2 from LAR is also inhibited. Therefore, the physical binding of FRS2 to LAR is enhanced by vanadate.
Discussion
LAR is a transmembrane RPTP and likely contributes to the regulation of tyrosine phosphorylation-mediated signal transduction. Genetic studies in Drosophila show that LAR may regulate cell adhesion-mediated signal transduction and guide neuron axon path ®nding (Krueger et al., 1996) . LAR knock-out studies in mice indicate that LAR may function to regulate mammary gland epithelial cell dierentiation. By overexpressing LAR in mammalian tissue culture cells, we have previously shown that LAR speci®cally dephosphorylates p130 CAS and plays a role in the regulation of cell adhesion-mediated survival signaling (Weng et al., 1998 (Weng et al., , 1999 . We now show that LAR also participates in regulation of the signaling pathways triggered by peptide growth factors. Furthermore, we show that the eects of LAR on the activation of MAPK induced by dierent peptide growth factors are distinct. While the FGF-induced MAPK activation is inhibited by LAR, the EGFinduced MAPK activation is not, providing the molecular basis for the diverse functions of LAR in dierent tissues. Our data also uncover the molecular mechanism by which LAR exerts its distinct eects on the signals generated by dierent peptide growth factors. Our data indicate that LAR does not directly dephosphorylate the growth factor receptors. Instead, the major substrates of LAR appear to be tyrosinephosphorylated adaptor proteins that act downstream of the receptor kinases. There are several lines of evidences from our data supporting that the signaling adaptor proteins FRS2 and a 180-kDa protein, in addition to p130 CAS , are direct in vivo substrates of LAR. First, LAR inhibits tyrosine phosphorylation of the two proteins. Second, LAR physically interacts with the two proteins. Third, the interactions of LAR with the two proteins are tyrosine phosphorylationdependent. By selectively dephosphorylating speci®c adaptor proteins, LAR controls the number and type of signaling complexes formed in response to dierent growth factors and thereby may contribute to signal speci®city.
On the basis of our data, we propose a model for LAR function in growth factor signaling (Figure 7 ). In the absence of LAR activity, both EGF and FGF induce the recruitment of GRB2 to the plasma membrane and activate the RAS-MAPK pathway. Activation of LAR results in the selective dephosphorylation by LAR of tyrosine-phosphorylated p130 CAS in EGF-stimulated cells and of tyrosinephosphorylated FRS2 and a 180-kDa protein (p180) in FGF-treated cells. Given that EGF induces the formation of several GRB2-containing signaling complexes, inhibition by LAR of the formation of only one of these complexes, GRB2-p130 CAS , is likely not sucient to aect MAPK activation. Selective inhibition of p130 CAS -mediated signals by LAR may aect biological activities of EGF in a cell type-or conditiondependent manner. On the other hand, inhibition by LAR of the phosphorylation of both FRS2 and p180 as well as of their interactions with GRB2 in FGFstimulated cells is likely to have a substantial impact on FGF-induced activation of MAPK. These dierential eects of LAR on peptide growth factor signaling may therefore contribute to the dierent biological activities elicited by dierent growth factors. Other RPTPs expressed in dierent cell types may act in a similar manner to regulate signaling by dierent ligands and signal transducers. In this regard, LAR reduced both the duration and extent of the FGF-induced activation of MAPK, the activity of which has been proposed as the determinant of cell dierentiation versus cell proliferation (Marshall, 1995) .
EGF induced the interaction of GRB2 with at least four distinct tyrosine-phosphorylated proteins, including the EGFR, SHC, and p130 CAS . Only the formation of the GRB2-p130 CAS complex was aected by LAR. The mechanism by which LAR achieves such speci®city remains unclear. It is possible that the subcellular localization of LAR determines its substrate accessibility. LAR and p130 CAS are colocalized along stress ®bers and at focal adhesions (Weng et al., 1999) , and this colocalization may facilitate the selective interac- . A similar mechanism may underlie the interaction of LAR with FRS2 and the unidenti®ed p180. Although the subcellular localizations of FRS2 and p180 are not known, the physical association of LAR with these two proteins suggests that all three are colocalized in vivo. In this regard, in addition to FRS2 and p180, a phosphotyrosinecontaining protein of 130 kDa was co-immunoprecipitated with LAR from FGF-stimulated, vanadatetreated cells. We investigated the possibility that this 130-kDa protein is p130
CAS by immunoblot analysis. However, antibodies to p130 CAS failed to detect the presence of this protein in the LAR immunoprecipitates. It is possible that the reagents used were not suciently sensitive to detect a low amount of p130 CAS in the LAR precipitates.
Previous studies in which the amount or activity of LAR was altered by speci®c antisense oligonucleotides or antibodies showed that such treatments aect the autophosphorylation of receptors for insulin (Mooney et al., 1997) , EGF, and hepatocyte growth factor (Kulas et al., 1996) , suggesting that these receptors are direct substrates of LAR. This conclusion thus diers from that of the present study. This apparent discrepancy may be attributable to the dierences between the studies in cell type and the methods for modulating LAR activity or abundance. Given that most growth factor receptors undergo internalization and degradation immediately after ligand binding, receptor dephosphorylation may not be an ecient way for cells to regulate the activities of the phosphorylated receptors. Regulation of the phosphorylation and activity of downstream signal transducers is more likely to be the major focus in control of the speci®city, strength, and duration of signaling.
In summary, our data suggest a mechanism by which tyrosine phosphorylation-mediated transmembrane signal transduction is regulated by RPTPs. The major cellular targets of RPTPs may thus be signal transducers that act downstream of the growth factor receptors, the same proteins targeted by these membrane-bound tyrosine kinases, rather than the receptors themselves. Dierent RPTPs may selectively interact with dierent signal transducers and thereby regulate the formation of signaling complexes formed in response to dierent extracellular stimuli. Such actions of RPTPs may de®ne the biological responses of a cell to a stimulant.
Materials and methods
Antibodies and reagents
Recombinant human EGF, a mouse monoclonal antibody (4G10) to phosphotyrosine (4G10), sheep polyclonal antibodies to the EGF receptor (EGFR), and an agaroseconjugated glutathione S-transferase (GST) fusion protein of p13 SUC1 were obtained from Upstate Biotechnology (Lake Placid, NY, USA). Recombinant human basic FGF was from Promega (Madison, WI, USA). Rabbit polyclonal antibodies to GRB2 and to FGF receptor 1 (FGFR1) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibodies to p130 CAS and to GRB2 were from Transduction Laboratories (Lexington, KY, USA). Rabbit polyclonal antibodies to phospho-MAPK were from New England BioLabs (Beverly, MA, USA). Wheat germ agglutinin (WGA)-conjugated Sepharose and a mouse monoclonal antibody (DM1A) to a-tubulin were from Sigma (St. Louis, MO, USA). Rabbit polyclonal antisera aC-292 and aN-130 are anti-LAR antisera raised against synthetic peptides of the C-terminus, the N-terminus of the LAR protein respectively; aLAR-294 is rabbit antiserum raised against a full-length LAR fusion protein (Yu et al., 1992) . All three anti-LAR antisera were used at 1 : 500 dilution. Antibodies purchased commercially were used as recommended by the manufacturers.
Cell culture and induction of LAR expression U2OS/LAR and U2OS/LAR-DP cells are human osteogenic sarcoma U2OS cells (American Type Culture Collection) stably transfected with inducible expression constructs encoding full-length or a phosphatase domain deletion mutant of rat LAR, respectively (Weng et al., 1998 (Weng et al., , 1999 . Both cell lines were maintained in DMEM (GIBCO-BRL) supplemented with 10% heat-inactivated fetal bovine serum, tetracycline (1 mg/ml), penicillin (50 U/ml), and streptomycin (5 mg/ml). Expression of LAR was induced by washing the cells, exposing them to trypsin, and then plating them in tetracycline-free medium for 24 h.
Pervanadate preparation and treatment
Pervanadate was prepared by mixing one part of 30% H 2 O 2 with nine parts of 20 mM sodium orthovanadate in modi®ed Tyrode's solution (150 mM NaCl, 4 mM KCl, 0.8 mM MgSO 4 , 1.8 mM CaCl 2 , 10 mM glucose, 30 mM HEPES, pH 7.5) and incubated at RT (228C) for 10 min, followed by addition of catalase (10 000 units/ml) to remove excess H 2 O 2 . The stock solution was added to the cells to give a ®nal concentration of 200 mM vanadate. The cells were treated with the freshly-made pervanadate for 10 min before addition of the growth factors.
Immunoblot analysis
Cells were lysed by direct addition of 16Laemmli sample buer containing 1 mM Na 3 VO 4 and boiling for 10 min. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (PAGE) on a 7.5% gel and transferred to a nitrocellulose membrane. For immunoblot analysis with monoclonal antibody 4G10 to phosphotyrosine, nonspeci®c sites on the membrane were blocked by incubation for 20 min at room temperature with 3% (w/v) nonfat dry milk in phosphate-buered saline. For immunoblot analysis with other antibodies, the membrane was incubated for 1 h at room temperature in a solution containing 10 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 0.1% (v/v) Tween 20. All membranes were then incubated overnight at 48C with primary antibodies in the same blocking solution. The membranes were then washed and incubated for 1 h at room temperature with horseradish peroxidase (HRP)-conjugated secondary antibodies (Promega). Immune complexes were detected by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).
Immunoprecipitation
For immunoprecipitation of GRB2 and LAR, cells were washed with ice-cold phosphate-buered saline and lysed in a solution containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (v/v) NP-40, 1 mM EGTA, 1 mM EDTA, 5 mM phenylmethylsulfonyl¯uoride, leupeptin (5 mg/ml), aprotinin (5 mg/ml), and 1 mM Na 3 VO 4 . For immunoprecipitation of the EGFR, cells were lysed in a modi®ed RIPA buer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 2.5% (w/v) sodium deoxycholate, 1 mM EGTA, 1 mM NaF, 5 mM phenylmethylsulfonyl¯uoride, leupeptin (5 mg/ml), aprotinin (5 mg/ml), 1 mM Na 3 VO 4 ]. Cell nuclei were removed from lysates by centrifugation for 10 min. Protein concentration was determined with the Bradford reagent (Bio-Rad). Cell lysate supernatants containing equal amounts of protein were used in each experiment. The supernatants (500 ml, containing 250 mg of protein) were ®rst incubated for 30 min at 48C with 1 mg of normal rabbit IgG plus 10 ml of protein A-conjugated beads (Santa Cruz Biotechnology) for polyclonal antibodies, or with 10 ml of protein A beads plus protein G beads for monoclonal antibodies. After removal of the beads by centrifugation, the supernatants were incubated overnight at 48C with appropriate primary antibodies and then for an additional 2 h in the presence of 10 ml of the corresponding beads. The beads were separated by centrifugation, washed three times with lysis buer, resuspended in 50 ml of Laemmli buer, and boiled for 10 min. Proteins were then resolved by SDS ± PAGE.
Precipitation of FRS2 was achieved by incubation of cell lysate supernatants (prepared in modi®ed RIPA buer) overnight at 48C with agarose-conjugated GST-p13 SUC1 (20 ml/ml), followed by centrifugation. For WGA-mediated precipitation, cells were lysed in RIPA buer [50 mM TrisHCl (pH 8.0), 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS], and the resulting lysates were centrifuged in a microcentrifuge for 20 min at 48C. A portion of the resulting supernatant (500 ml, containing 250 mg of protein) was incubated on a rotary shaker for 2 h at 48C with 0.6 mg of WGA-Sepharose. The beads were then separated by centrifugation, washed three times with RIPA buer, resuspended in 50 ml of Laemmli buer, and boiled for 10 min. Proteins were resolved by SDS ± PAGE.
